Keros to Receive $20M Takeda Milestone for ELRiSE MF Trial, Plans 25% Stockholder Distribution
KROS sits 17% above its 52-week low of $9.69.
Summary
Keros will receive a $20M milestone from Takeda for the ELRiSE MF trial and plans to distribute 25% of net proceeds to stockholders.
Key Events · Product Development and Regulatory · KROS
-
Second $20M Takeda Milestone Earned
Keros will receive $20M for dosing the first patient in the Phase 3 ELRiSE MF trial in myelofibrosis — a different trial than the July 30, 2026 milestone for the ELRiSE trial.
-
25% Stockholder Distribution Planned
Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders following receipt, leaving roughly $15M on the balance sheet.
-
Cash Runway Extended
The milestone adds to the $257.6M cash balance reported in Q2 2026, further extending runway into mid-2028.
-
Elritercept Partnership Progress
This is the second milestone under the Takeda license agreement effective January 16, 2025, which included a $200M upfront payment and potential milestones exceeding $1.1B.
Analysis · KROS · Life Sciences
Keros earned a second $20 million development milestone from Takeda — this one for dosing the first patient in the Phase 3 ELRiSE MF trial in myelofibrosis, a different indication than the July 30 milestone. The company also committed to distribute 25% of net proceeds to stockholders, an unusual direct return of capital for a clinical-stage biotech. The milestone extends the cash runway and validates the elritercept partnership, but the distribution commitment means only ~$15M stays on the balance sheet.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KROS was trading at $11.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.7M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.